When is biologic therapy recommended for pyoderma gangrenosum?

Pyoderma gangrenosum is an inflammatory ulcerating skin condition. A biologic medicine targets selected immune signals that can drive inflammation. A dermatologist may discuss it when the wound burden is substantial, healing is difficult, or standard anti-inflammatory treatment has not provided enough control. The choice depends on the ulcer pattern, other illnesses, medicines, infection concerns, and whether an associated inflammatory disease is present.

Arrange assessment with a dermatologist experienced in inflammatory skin ulcers. Bring a list of medicines and medical conditions, and mention bowel symptoms, joint pain, eye inflammation, or a history of immune problems. The clinician may review the diagnosis, examine the ulcer, organise checks before immune-targeting treatment, and combine the plan with wound care and pain control. Do not stop prescribed medicines or apply irritating products to the ulcer without guidance.

Seek prompt medical care if an ulcer is enlarging quickly, pain is escalating, the surrounding skin becomes hot or increasingly red, drainage develops, or you feel feverish or unwell. A new ulcer after an injury or procedure also deserves timely review because trauma can aggravate this condition. Emergency assessment is appropriate for heavy bleeding, faintness, confusion, or severe illness.

Ask which features of your ulcer make a biologic reasonable, what alternatives are available, how wound care will fit alongside it, and which warning signs should be reported. You can also ask how treatment response will be monitored and what to do if an infection is suspected.